Clinical Trial: NCT04981899
PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin Lymphoma
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | St. Petersburg State Pavlov Medical University |
| Information Provided By: | St. Petersburg State Pavlov Medical University |
| Last Update Posted: | 2026-10-28 |
Study Overview
Brief Summary
Nivolumab is an anti-PD-1 antibody with high activity in patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL). A PET-adapted strategy using nivolumab with ICE added for patients without complete response has shown high response rates and favorable progression-free survival as a bridge to autologous stem cell transplantation, while allowing omission of salvage chemotherapy in a substantial proportion of patients. This study evaluates the safety and efficacy of a PET-adapted strategy using fixed-dose nivolumab 40 mg, with ifosfamide, carboplatin, and etoposide (NICE-40) administered to patients without complete response to nivolumab monotherapy.
Official Title
Conditions
Intervention / Treatment
- Drug: Nivolumab
- Drug: Ifosfamide
- Drug: Carboplatin
- Drug: Etoposide
Other Study ID Numbers
- r/r cHL NICE-40
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | St. Petersburg State Pavlov Medical University |
| Information Provided By: | St. Petersburg State Pavlov Medical University |
| Last Update Posted: | 2026-10-28 |
Study Overview
Brief Summary
Nivolumab is an anti-PD-1 antibody with high activity in patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL). A PET-adapted strategy using nivolumab with ICE added for patients without complete response has shown high response rates and favorable progression-free survival as a bridge to autologous stem cell transplantation, while allowing omission of salvage chemotherapy in a substantial proportion of patients. This study evaluates the safety and efficacy of a PET-adapted strategy using fixed-dose nivolumab 40 mg, with ifosfamide, carboplatin, and etoposide (NICE-40) administered to patients without complete response to nivolumab monotherapy.
Official Title
Conditions
Intervention / Treatment
- Drug: Nivolumab
- Drug: Ifosfamide
- Drug: Carboplatin
- Drug: Etoposide
Other Study ID Numbers
- r/r cHL NICE-40